在USP7中,KRAS被二氧化化,并促进非小细胞肺癌
Bin Huang1, Dan Cao1, Xiao Yuan2
1State Key Laboratory of Chemical Oncogenomics, Laboratory of Structural Biology and Drug Discovery, Laboratory of Ubiquitination and Targeted Therapy, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, Guangdong 518055, China.
Cell reports
|November 5, 2024
概括
乌比基特异性蛋白酶7 (USP7) 双基化KRAS,增强非小细胞肺癌 (NSCLC) 细胞增殖. 针对USP7提供了一个有希望的策略来对抗NSCLC中KRAS抑制剂耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 癌症性RAS突变驱动瘤发生.
- 乌比基化调节了RAS蛋白的功能,但对乌比基化了解较少.
- 克拉斯是非小细胞肺癌 (NSCLC) 的关键瘤基因.
研究的目的:
- 调查duebiquitination在RAS调节中的作用.
- 为了识别针对KRAS的脱化酶.
- 探索USP7作为NSCLC的治疗点.
主要方法:
- 生物化学试验用于研究KRAS无化和脱化.
- 蛋白质与蛋白质相互作用研究 (USP7-KRAS结合).
- 在NSCLC细胞系中进行细胞增殖测定.
- 分析患者瘤组织的USP7和KRAS相关性.
主要成果:
- USP7直接在K147处对KRAS进行二基化,去除与K48结合的多基链.
- USP7稳定了KRAS,促进了NSCLC细胞的增殖.
- 高USP7表达与KRAS相关,NSCLC患者的生存率较差.
- 抑制USP7抑制NSCLC的扩散,克服了对KRAS-G12C抑制剂的抵抗力.
结论:
- USP7 是一个关键的二维基因酶,调节KRAS的稳定性和功能.
- 针对USP7是NSCLC的潜在治疗策略.
- 抑制USP7可能会克服对现有的KRAS向疗法的耐药性.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K


